Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garry M Walsh

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Therapeutics and Clinical Risk Management|August 30, 2008
[Not Available]Garry M Walsh
Immunotherapy|July 20, 2010
Reslizumab for pediatric eosinophilic esophagitisGarry M Walsh
Current Opinion in Investigational Drugs (London, England : 2000)|December 16, 2010
Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPDGarry M Walsh
Recent Patents on Inflammation & Allergy Drug Discovery|September 1, 2010
Antagonism of eosinophil accumulation in asthmaGarry M Walsh
Expert Review of Clinical Immunology|July 27, 2016
Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an updateGarry M Walsh
American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions|January 15, 2004
Second-generation antihistamines in asthma therapy: is there a protective effect?Garry M Walsh
Therapeutics and Clinical Risk Management|March 25, 2008
EditorialGarry M Walsh
Therapeutics and Clinical Risk Management|June 3, 2008
[Not Available]Garry M Walsh
Therapeutics and Clinical Risk Management|May 20, 2008
EditorialGarry M Walsh
Frontiers in Pharmacology|November 29, 2012
Antagonism of cytokine-induced eosinophil accumulation in asthmaGarry M Walsh
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Therapeutics and Clinical Risk Management|August 30, 2008
[Not Available]Garry M Walsh
Immunotherapy|July 20, 2010
Reslizumab for pediatric eosinophilic esophagitisGarry M Walsh
Current Opinion in Investigational Drugs (London, England : 2000)|December 16, 2010
Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPDGarry M Walsh
Recent Patents on Inflammation & Allergy Drug Discovery|September 1, 2010
Antagonism of eosinophil accumulation in asthmaGarry M Walsh
Expert Review of Clinical Immunology|July 27, 2016
Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an updateGarry M Walsh
American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions|January 15, 2004
Second-generation antihistamines in asthma therapy: is there a protective effect?Garry M Walsh
Therapeutics and Clinical Risk Management|March 25, 2008
EditorialGarry M Walsh
Therapeutics and Clinical Risk Management|June 3, 2008
[Not Available]Garry M Walsh
Therapeutics and Clinical Risk Management|May 20, 2008
EditorialGarry M Walsh
Frontiers in Pharmacology|November 29, 2012
Antagonism of cytokine-induced eosinophil accumulation in asthmaGarry M Walsh
Pageof 6